Tandem Diabetes Care (TNDM) Operating Income Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.70% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 7.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 34.83% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 75.54% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -2.70% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -24.91% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 48.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.52% |
| Dec 31, 2025 | 35.11% |
| Sep 30, 2025 | 21.63% |
| Jun 30, 2025 | -61.77% |
| Mar 31, 2025 | -99.00% |
| Dec 31, 2024 | -26.94% |
| Sep 30, 2024 | -75.22% |
| Jun 30, 2024 | -97.17% |
| Mar 31, 2024 | -134.38% |
| Dec 31, 2023 | -57.12% |
| Sep 30, 2023 | -215.03% |
| Jun 30, 2023 | -47.73% |
| Mar 31, 2023 | -111.17% |
| Dec 31, 2022 | -117.52% |
| Sep 30, 2022 | -99.25% |
| Jun 30, 2022 | -87.22% |
| Mar 31, 2022 | -11.73% |
| Dec 31, 2021 | 183.34% |
| Sep 30, 2021 | 35.57% |
| Jun 30, 2021 | 33.66% |
| Mar 31, 2021 | 40.65% |
| Dec 31, 2020 | 58.04% |
| Sep 30, 2020 | 57.52% |
| Jun 30, 2020 | 14.07% |
| Mar 31, 2020 | 13.85% |
| Dec 31, 2019 | 29.28% |
| Sep 30, 2019 | 40.44% |
| Jun 30, 2019 | 52.18% |
| Mar 31, 2019 | 17.01% |
| Dec 31, 2018 | 27.03% |
| Sep 30, 2018 | 5.65% |
| Jun 30, 2018 | 9.16% |
| Mar 31, 2018 | 8.79% |
| Dec 31, 2017 | 18.19% |
| Sep 30, 2017 | 11.52% |
| Jun 30, 2017 | -1.17% |
| Mar 31, 2017 | -0.62% |
| Dec 31, 2016 | 6.76% |
| Sep 30, 2016 | -32.82% |
| Jun 30, 2016 | -7.63% |
| Mar 31, 2016 | -38.98% |